AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25008853
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg daily)
Trial: 17700424
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG) powder containing 60 million cells, twice daily for a minimum period of 7 days
Trial: 11176329
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) alone
Trial: 2254222
Drug: Clindamycin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (300 mg qid for one day)
Trial: 7357803
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg every 8 hr for 1 wk
Trial: 7357803
Drug: Acebutolol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 300 mg every 8 hr for 1 wk
Trial: 28115517
Drug: Renal denervation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal denervation plus stepped-care antihypertensive treatment
Trial: 28115517
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stepped-care treatment alone)
Trial: 19757270
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (2 tabs of 200 microg)
Trial: 19757270
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (20 units at 10 cc/min)
Trial: 2920499
Drug: Yohimbine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (4 mg t.i.d.)
Trial: 20003300
Drug: Health coaching,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health coaching, home blood pressure monitoring, and home-titration of antihypertensive medications
Trial: 17258358
Drug: Pneumococcal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal protein D conjugate vaccine
Trial: 7766747
Drug: Lactulose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (30 g)
Trial: 14658595
Drug: Colour Doppler
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colour Doppler ultrasound with contrast agents
Trial: 7740055
Drug: Triazolam (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125 or 0.25 mg per capsule)
Trial: 7740055
Drug: Triazolam (0.0312-0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.0312-0.25 mg per capsule)
Trial: 7740055
Drug: Experimenter-administered doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimenter-administered doses of triazolam
Trial: 7023592
Drug: Physostigmine 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.375 mg
Trial: 7023592
Drug: Arecoline 4
RxNorm normalized name: bethanechol chloride Injectable Solution [Urecholine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline 4 mg
Trial: 7023592
Drug: Physostigmine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.25 mg
Trial: 7023592
Drug: Physostigmine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 0.75 mg
Trial: 7023592
Drug: Arecoline 2
RxNorm normalized name: bethanechol chloride Injectable Solution [Urecholine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline 2 mg
Trial: 31018173
Drug: Two-step stannous
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step stannous fluoride dentifrice and hydrogen peroxide whitening gel system, interactive oscillating-rotating electric toothbrush, and expanded polytetrafluoroethylene floss
Trial: 26604072
Drug: Finerenone 1-40
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone 1-40 mg PEG solution
Trial: 26604072
Drug: Finerenone 10
RxNorm normalized name: finerenone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 10 mg IR tablet
Trial: 26604072
Drug: Finerenone 80
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone 80 mg (eight × finerenone 10 mg IR tablets)
Trial: 22408123
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (0.01 mg/kg per day for the first week, 0.02 mg/kg per day for the second week, and 0.03 mg/kg per day for the third week)
Trial: 22408123
Drug: Pegvisomant treatment
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvisomant treatment (10 mg/day for the first week and 15 mg/day for the last two weeks)
Trial: 18520979
Drug: Tetrabenazine (TBZ)
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ) treatment withdrawal
Trial: 18520979
Drug: Partial or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial or no withdrawal of TBZ treatment
Trial: 23237982
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg daily
Trial: 16135901
Drug: Efavirenz 800
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 800 mg daily
Trial: 16135901
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (600 mg and 800 mg)
Trial: 7586338
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg/d, titrated to 40 and then to 80 mg during the first 16 weeks)
Trial: 7021057
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal dental treatment)
Trial: 31755431
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 1 mg/kg/day titrated to 3 mg/kg/day over 1 week, continued for 6 months and tapered over 1 week
Trial: 31755431
Drug: Intralesional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional propranolol hydrochloride 1 mg/ml; 0.2 ml/cm, 3 doses 4-6 weeks apart
Trial: 19427992
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab
Trial: 26116264
Drug: Intravitreal anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal anti-VEGF medications (ranibizumab and bevacizumab)
Trial: 21846439
Drug: Estrogen cream
RxNorm normalized name: ESTRIOL 4 mg in 85 g / ESTRADIOL 1 mg in 85 g TRANSDERMAL CREAM [BiEST 5.0 Estrogen Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen cream (3 g of vaginal cream containing 1.875 g of conjugated estrogens for six weeks)
Trial: 21846439
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (comparable cream without estrogens for six weeks)
Trial: 19210012
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD), 10 to 12 sessions
Trial: 19210012
Drug: Enhanced Treatment
RxNorm normalized name: Thera-M Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment as Usual (ETAU), single-session intervention
Trial: 1518670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group given narcotic-sedative premedication
Trial: 6097117
Drug: Cefmenoxime (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmenoxime (0.5 to 2.0 g every six hours)
Trial: 6097117
Drug: Cefoxitin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (0.5 to 2.0 g every six hours)
Trial: 30927417
Drug: Ganirelix 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix 0.25 mg/day
Trial: 28687937
Drug: Combined nutraceutical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nutraceutical (red yeast rice 10 mg, phytosterols 800 mg, L-tyrosol 5 mg)
Trial: 19555395
Drug: Telmisartan (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40-80 mg/day)
Trial: 19555395
Drug: Bisoprolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5-10 mg/day)
Trial: 11371728
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-D-glucose (2-DG) infusion
Trial: 8005128
Drug: Ramipril treatment
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril treatment for 12 weeks
Trial: 2585534
Drug: 0.5 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/m3 respirable activated carbon aerosol
Trial: 1094748
Drug: Topically-applied buphenin
RxNorm normalized name: buphenine
DrugBank: Nylidrin (DB06152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically-applied buphenin (in a gel basis)
Trial: 12372443
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (3.75 mg i.m. every 28 days for 3 months)
Trial: 10674010
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 30 mg daily for 1 year
Trial: 10674010
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles) + TAM
Trial: 10674010
Drug: CMF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles)
Trial: 31937160
Drug: Rectal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal progesterone 200 mg daily until 36+6 weeks or spontaneous delivery
Trial: 15991504
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in a similar manner
Trial: 31680085
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment combined with benzbromarone
Trial: 30672211
Drug: Pestle needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pestle needling therapy, applied once daily for 4 weeks.
Trial: 30672211
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and nursing for diabetes (Control group).
Trial: 22679715
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Bacillus licheniformis and Deanxit)
Trial: 18046717
Drug: 72 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 72 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Trial: 18046717
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Trial: 10890258
Drug: Fosfomycin (3-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (3-g single dose)
Trial: 10890258
Drug: Nitrofurantoin (100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (100-mg capsules for 7 days)
Trial: 7724749
Drug: L‐DOPA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐DOPA alone (n = 16)
Trial: 7724749
Drug: C‐11‐L‐DOPA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐11‐L‐DOPA and C‐11‐5‐HTP (n = 6)
Trial: 2075773
Drug: Perioperative short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative short-term antibiotic prophylaxis
Trial: 2075773
Drug: Postoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotic treatment
Trial: 30787601
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg SBB‐PE
Trial: 26997182
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse trajectory
Trial: 22381604
Drug: Immediate medical
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate medical treatment (oral mifepristone followed by vaginal misoprostol, n = 91)
Trial: 22381604
Drug: Sequential management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential management (1 week of watchful waiting followed by medical treatment if necessary, n = 91)
Trial: 22381604
Drug: Immediate medical
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate medical treatment
Trial: 22381604
Drug: Sequential management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential management
Trial: 12112798
Drug: salbutamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol plus BDP 200 microg bid by metered dose inhaler (MDI) with a spacer
Trial: 1798317
Drug: Caffeine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (10 mg.kg‐1) taken immediately prior to exercise
Trial: 26886503
Drug: Usual drug
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual drug education program (control group)
Trial: 25046272
Drug: Subcutaneous MNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous MNX (0.9 mg/kg)
Trial: 17927497
Drug: Fish oil,
RxNorm normalized name: Fish Oil, oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil, 2 g tid plus placebo capsules bid (n = 12)
Trial: 17927497
Drug: Fish oil,
RxNorm normalized name: Fish Oil, oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil, 2 g tid plus celecoxib 200 mg bid (n = 10)
Trial: 11856592
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with bone marrow or stem cell support
Trial: 11856592
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent chemotherapy (doxorubicin, epirubicin, ifosfamide)
Trial: 8180354
Drug: Anticytokine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticytokine treatment
Trial: 8180354
Drug: Antiprotease treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiprotease treatment
Trial: 1819435
Drug: AIK-C vaccine
RxNorm normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIK-C vaccine at 4-5 months
Trial: 1819435
Drug: Edmonston-Zagreb vaccine
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb vaccine at 4-5 months
Trial: 1819435
Drug: High-dose Schwarz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Schwarz vaccine at 4-5 months
Trial: 1819435
Drug: High-dose Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Edmonston-Zagreb vaccine for seropositive children
Trial: 1819435
Drug: AIK-C vaccine
RxNorm normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIK-C vaccine for seropositive children
Trial: 1819435
Drug: Schwarz vaccine
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz vaccine for seropositive children
Trial: 1819435
Drug: AIK-C vaccine
RxNorm normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIK-C vaccine at 8-10 months
Trial: 1819435
Drug: Schwarz vaccine
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz vaccine at 8-10 months
Trial: 19833566
Drug: Leukocytapheresis (LAP)
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytapheresis (LAP) plus steroids
Trial: 19032173
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g piperacillin
Trial: 19032173
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g piperacillin
Trial: 15927814
Drug: FX cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX cream (0.02% farnesol and 5% xylitol)
Trial: 12831141
Drug: Latanoprost (topically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (topically applied once daily in the evening for 12 weeks)
Trial: 12831141
Drug: Brimonidine (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine (applied twice daily for 6 weeks, with 16 patients continuing for 12 weeks)
Trial: 8796775
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (50 micrograms)
Trial: 8382104
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day for an average of 8 days)
Trial: 22156181
Drug: Additional written
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional written information about orthodontic treatment
Trial: 20112575
Drug: Cheezheng Qingpeng
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheezheng Qingpeng ointment
Trial: 16936533
Drug: Low-dose fixed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fixed combination of perindopril 2 mg and indapamide 0.625 mg
Trial: 16936533
Drug: Standard guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guidelines based therapy for glucose control
Trial: 11783459
Drug: Herbal anticellulite
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal anticellulite pill plus supplements of conjugated linoleic acid
Trial: 11783459
Drug: Herbal anticellulite
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal anticellulite pill
Trial: 1651610
Drug: Serotype 1
RxNorm normalized name: Aspergillus fumigatus serotype 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 1 reassortant vaccine (10^4 p.f.u.)
Trial: 1651610
Drug: Serotype 2
RxNorm normalized name: Pneumococcal polysaccharide serotype 23F
DrugBank: Streptococcus pneumoniae type 23f capsular polysaccharide antigen (DB10340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 2 reassortant vaccine (10^4 p.f.u.)
Trial: 1651610
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serotype 1 and serotype 2 vaccines (0.5 x 10^4 p.f.u. of each)
Trial: 1651610
Drug: Trivalent combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent combination (0.33 x 10^4 p.f.u. of each strain)
Trial: 1651610
Drug: Various vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various vaccines and combinations
Trial: 6321376
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ORG 2766
Trial: 25132516
Drug: PEGASUS psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGASUS psychoeducational programme (n = 24), administered in six weekly group sessions.
Trial: 24001010
Drug: Spontaneous inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous inhibitor clearance in patients not undergoing ITI
Trial: 24001010
Drug: Inhibitor titre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor titre and gene mutation
Trial: 24001010
Drug: Cumulative incidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative incidence of inhibitors
Trial: 24001010
Drug: Permanent inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent inhibitors
Trial: 24001010
Drug: Transient inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient inhibitors